1 / 43

Lecture Title: Peri-operative Fluid Therapy and Blood Transfusion Practice

Lecture Title: Peri-operative Fluid Therapy and Blood Transfusion Practice. Lecturer name: A. Dawlatly E-Mail: dawlatly@ksu.edu.sa Lecture Date : 16/10/1433. Response of CVP/PAOP to increase in intra-vascular volume.

phyllisp
Télécharger la présentation

Lecture Title: Peri-operative Fluid Therapy and Blood Transfusion Practice

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Lecture Title:Peri-operative Fluid Therapy and Blood Transfusion Practice Lecturer name: A. Dawlatly E-Mail: dawlatly@ksu.edu.sa Lecture Date: 16/10/1433

  2. Response of CVP/PAOP to increase in intra-vascular volume

  3. Stroke volume response to an increased intravascular volume (Frank-Starling curve)

  4. Lecture Objectives Students at the end of the lecture will be able to: -Describe different fluids components -Describe the challenges of Fluid therapy -Answer FAQ

  5. FAQs -Crystalloids vs Colloids -Role of plasma volume expander in septic shock -Why dose limit for colloids -For how long HES -Does HES reduce capillary leak -Renal and liver functions

  6. FLUID LOSSES -TRAUMA -BURNS -PERITONITIS -BLEEDING

  7. Final Goals of Fluid resuscitation -Achievement of normovolemia& hemodynamic stability -Correction of major acid-base disturbances -Compensation of internal fluid fluxes -Maintain an adequate gradient between COP&PCWP -Improvement of microvascular blood flow -Prevention of cascade system activation -Normalization of O2 delivery -Prevention of reperfusion cellular injury -Achievement of adequate urine output

  8. Desirable outcome of fluid resuscitation - No peripheral edema - No ARDS

  9. Undesirable PMN-EC interaction Activation Degranulation Elastase&O2 radicals EC damage (lysis & detachment) Leak

  10. Characteristics of different volume substitutes -IVVP Cryst<Gel<Dex<HSS -Coag Cryst<Alb<Gel=HES<Dex -Anaphyl Cryst<HES=Alb<Dex<Gel -Cost Cryst=Gel<HES<Dex<Alb

  11. Crystalloids in traumaAdvantages: -Balanced electrolyte solutions -Buffering capacity (Lactate) -Easy to administer -No risk of adverse reactions -No disturbance of hemostasis -Promote diuresis -Inexpensive

  12. Crystalloids contin…Disadvantages: -Poor plasma volume support -Large quantities needed -Risk of Hypothermia -Reduced plasma COP -Risk of edema

  13. Crystalloid solutionsNaCl Isotonic 0.9%: 9g/l , Na 154, Cl 154, Osmolarity: 304mosmol/l Disadvantages: Hyper-chloremic acidosis

  14. Hypertonic saline Advantages: -Small volume for resuscitation. -Osmotic effect -Inotropic effect -Direct vasodilator effect -Increase MAP, CO -Increase renal, mesenteric,splanchnic, coronary blood flow. Disadvantages: increase hemorrhage from open vessels. Hypernatremia Hyperchloremia. Metabolic acidosis.

  15. CrystalloidsLactated Ringer's Composition: Na 130, cl 109, K 4, ca 3, Lactate 28, Osmolarity 273mosmol/l -Sydney Ringer 1880 -Hartmann added Lactate=LR -Minor advantage over NaCl Disadvantages: -Not to be used as diluent for blood (Ca citrate) -Low osmolarity, can lead to high ICP

  16. CrystalloidsDextrose 5% Composition: 50g/l, provides 170kcal/l Disadvantages: -enhance CO2 production -enhance lactate production -aggravate ischemic brain injury

  17. Colloids Advantages: -Good IVVP -Prolonged plasma volume support -Moderate volume needed -minimal risk of tissue edema -enhances microvascular flow

  18. Colloids Disadvantages: -Risk of volume overload -Adverse effect on hemostasis -Adverse effect on renal function -Anaphylactic reaction -Expensive

  19. Dextran Composition: 40/70 Inhibit platelet aggregation bleeding

  20. MRI sagittal view: epid hematoma T12-T9 MRI Transverse view: epid hematoma at T12 Medscape 16/09/03

  21. Gelatins -Derived from hydrolyzed bovine collagen -Metabolized by serum collagenase -0.5-5hr -Histamine release (H1 blockers recommended) -Decreases Von W factor (VWF) -Bovine Spongiform Encephalopathy 1:1,000.000

  22. Albumin -Heat treated preparation of human serum -5% (50g/l), 25% (250g/l) -Half of infused volume will stay intravascular -COP=20mmHg=plasma -25%, COP=70mmHg, it will expand the vascular space by 4-5 times the volume infused -25% used only in case of hypoalbuminemia

  23. Starch MW DS Max dose Hetastarch 240,000 0.7 1,500/day Pentastarch 200,000 0.5 2,500/day Tetrastarch 130,000 0.4 3,500//day (Voluven)

  24. Crystalloids Colloids IVVP Poor Good Hemod Stability Transient Prolong Infusate volume Large Moderate Plasma COP Reduced Maintain Tissue edema Obvious Insignific Anaphylaxis Non-exist low-mod Cost Inexpensive Expensive

  25. Crystalloids OR Colloids ACS protocol for ATLS: replace each ml of blood loss with 3 ml of crystalloid fluid. 3 for 1 rule. Patient response: -Rapid -Transient -Non-responsive

  26. Blood Transfusion (up to 30% of blood volume can be treated with crystalloids) Why? -Improvement of oxygen transport -Restoration of red cell mass -Correction of bleeding caused by platelet dysfunction -Correction of bleeding caused by factor deficiencies

  27. Massive Transfusion (MT) Definition: Transfusion of at least one blood volume or 10 units of blood in a 24 hr period

  28. Pathophysiology of coagulopathy in MT -Hemodilution -Hypothermia -Blood components and alteration of hemostasis

  29. DIC Type Definition Diagnosis Lab Biological Hemostatic defect high D-Dimers and DD≥500ug/l without clinical SS major or minor criteria Plat 50-100,000 of platelet consumption Clinical Hemostatic defect+He same above+microvasc INR 1.2-1.5 bleeding Complicated+ischemia +organ failure

  30. Auto-transfusion Techniques: -Pre-deposit transfusion -Intra-operative acute normovolemic hemodilution -Intra-operative cell salvage

  31. Pre-deposit transfusion -blood collection begins 3-5 weeks preoperatively -2-4 units stored -Eliminates risk of viral transmission -Reduces risk of immunological reactions -Collection is expensive and time consuming -Only suitable for elective surgery

  32. Intra-operative acute normovolemic hemodilution -Whole blood removed at start of surgery -1-1.5L can be collected -Blood stored in OR -Re-infused during or after surgery -Cheaper than pre-deposit -Little risk of clerical error -Suitable for elective surgery

  33. Intra-operative cell salvage -shed blood is collected from surgical field -heparin added -cells washed with saline and concentrated by centrifugation. -concentrate transfused -large volume could be used -platelets and clotting factors are consumed -suitable for cardiac surgery -contraindicated in contaminated surgical field

  34. FFP -Is plasma removed from a unit of whole blood and frozen at or below –18C within 8hr of collection -It contains all coagulation factors in normal amounts and is free of red cells, leukocytes and platelets -It is not a concentrate of clotting factors. One unit is 225ml and must be ABO compatible, Rh not considered -1ml/kg will raise most clotting factors by 1%. -Should be used within 24hr after thawing

  35. Cryoprecipitate -Is low purity concentrate of 3 hemostatic proteins prepared from donated whole blood -A single bag Cryo contains: 100units factor VIII and VWF+150-250mg fibrinogen with XIII and fibronectin -No compatibilty test required -Indication: hypo-fibrinogenemia<100mg/dl

  36. Complications of Blood Transfusion Immune complications: -hemolytic (acute and delayed) -non-hemolytic (febrile, urticaria, anaphylactic, purpura, immune suppression) Non-Immune complications: -Complications associated with massive blood transfusion: coagulopathy, citrate toxicity, hypothermia, acid-base balance, serum K -Infectious complications: hepatitis, AIDS, other viral agents (CMV,EBV,HTLV), parasites and bacteria..

  37. Reference book and Journal reference -American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies. Practice guidelines for perioperative blood transfusion and adjuvant therapies. Approved October 22, 1995, last amended October 25, 2005. Available at http://www.asahq.org/publicationsAndServices/practiceparam.htm#blood. Accessed January 22, 2006. - Grocott M et al. Perioperative fluid management and clinical outcomes in adults. Anesthesia Analgesia 2005;100:1093-106

  38. Thank You 

More Related